12:00 AM
 | 
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xalkori crizotinib regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against the use of Xalkori crizotinib from Pfizer to treat previously treated, anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) - its approved indication. Even...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >